{"data":[{"accessionNo":"0000315066-26-002325","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0000744218","issuerName":"CELLDEX THERAPEUTICS INC","ticker":"CLDX","cusip":"15117B202","securityClass":"COMMON STOCK","eventDate":"2026-09-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":8411905.03,"percentOfClass":10.7,"filedAt":"2026-10-07","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000315066-26-002325","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0000744218","issuerName":"CELLDEX THERAPEUTICS INC","ticker":"CLDX","cusip":"15117B202","securityClass":"COMMON STOCK","eventDate":"2026-09-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":8411905.03,"percentOfClass":10.7,"filedAt":"2026-10-07","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001907884-26-000013","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":"15117B202","securityClass":"Common Stock, par value $0.001","eventDate":"2026-06-30","reportingPerson":"Kynam Capital Management, LP","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":6.78,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001907884-26-000013","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":"15117B202","securityClass":"Common Stock, par value $0.001","eventDate":"2026-06-30","reportingPerson":"Kynam Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":6.78,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001907884-26-000013","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":"15117B202","securityClass":"Common Stock, par value $0.001","eventDate":"2026-06-30","reportingPerson":"Yue Tang","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":6.78,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000080255-26-000537","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0000744218","issuerName":"CELLDEX THERAPEUTICS INC","ticker":"CLDX","cusip":"15117B202","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":4686187,"percentOfClass":6,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001907884-26-000009","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":"15117B202","securityClass":"Common Stock, par value $0.001","eventDate":"2026-03-31","reportingPerson":"Kynam Capital Management, LP","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":8.77,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001907884-26-000009","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":"15117B202","securityClass":"Common Stock, par value $0.001","eventDate":"2026-03-31","reportingPerson":"Yue Tang","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":8.77,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001907884-26-000009","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":"15117B202","securityClass":"Common Stock, par value $0.001","eventDate":"2026-03-31","reportingPerson":"Kynam Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":8.77,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001104659-26-062330","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":"15117B202","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Bellevue Asset Management AG","reportingCik":null,"personType":"CO","sharesOwned":1200000,"percentOfClass":1.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001104659-26-062330","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":"15117B202","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Bellevue Group AG","reportingCik":null,"personType":"HC,CO","sharesOwned":1200000,"percentOfClass":1.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000093751-26-000217","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0000744218","issuerName":"CELLDEX THERAPEUTICS INC","ticker":"CLDX","cusip":"15117B202","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":2804168,"percentOfClass":4.2,"filedAt":"2026-05-12","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000315066-26-001146","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0000744218","issuerName":"CELLDEX THERAPEUTICS INC","ticker":"CLDX","cusip":"15117B202","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":3749048.03,"percentOfClass":5.6,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000315066-26-001146","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0000744218","issuerName":"CELLDEX THERAPEUTICS INC","ticker":"CLDX","cusip":"15117B202","securityClass":"COMMON STOCK","eventDate":"2026-03-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":3749048.03,"percentOfClass":5.6,"filedAt":"2026-05-06","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0002100119-26-000279","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics Inc","ticker":"CLDX","cusip":"15117B202","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vanguard Capital Management","reportingCik":null,"personType":"IA","sharesOwned":3446795,"percentOfClass":5.17,"filedAt":"2026-04-29","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000102909-26-000983","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics Inc","ticker":"CLDX","cusip":"15117B202","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-26","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000902664-26-001544","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1758357,"percentOfClass":2.6,"filedAt":"2026-03-10","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000902664-26-001544","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":1758357,"percentOfClass":2.6,"filedAt":"2026-03-10","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000902664-26-001544","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":1758357,"percentOfClass":2.6,"filedAt":"2026-03-10","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000902219-26-000058","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Wellington Management Group LLP","reportingCik":null,"personType":"HC","sharesOwned":8079608,"percentOfClass":12.2,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000902219-26-000058","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Wellington Group Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":8079608,"percentOfClass":12.2,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000902219-26-000058","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Wellington Investment Advisors Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":8079608,"percentOfClass":12.2,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000902219-26-000058","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"Wellington Management Company LLP","reportingCik":null,"personType":"IA","sharesOwned":8079608,"percentOfClass":11.8,"filedAt":"2026-02-10","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000093751-26-000033","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0000744218","issuerName":"CELLDEX THERAPEUTICS INC","ticker":"CLDX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":3397713,"percentOfClass":5.1,"filedAt":"2026-02-09","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001104659-25-112821","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-08-18","reportingPerson":"Bellevue Group AG","reportingCik":null,"personType":"HC,CO","sharesOwned":3617669,"percentOfClass":5.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001104659-25-112821","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-08-18","reportingPerson":"Bellevue Asset Management AG","reportingCik":null,"personType":"CO","sharesOwned":3617669,"percentOfClass":5.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001831942-25-000031","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock, par value $.001","eventDate":"2025-09-30","reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":3028335,"percentOfClass":4.6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0001831942-25-000031","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock, par value $.001","eventDate":"2025-09-30","reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":3028335,"percentOfClass":4.6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000080255-25-000800","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0000744218","issuerName":"CELLDEX THERAPEUTICS INC","ticker":"CLDX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":2382701,"percentOfClass":3.6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000902219-25-000372","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-10-31","reportingPerson":"Wellington Management Group LLP","reportingCik":null,"personType":"HC","sharesOwned":7394746,"percentOfClass":11.1,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000902219-25-000372","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-10-31","reportingPerson":"Wellington Group Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":7394746,"percentOfClass":11.1,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000902219-25-000372","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-10-31","reportingPerson":"Wellington Investment Advisors Holdings LLP","reportingCik":null,"personType":"HC","sharesOwned":7394746,"percentOfClass":11.1,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"},{"accessionNo":"0000902219-25-000372","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0000744218","issuerName":"Celldex Therapeutics, Inc.","ticker":"CLDX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-10-31","reportingPerson":"Wellington Management Company LLP","reportingCik":null,"personType":"IA","sharesOwned":7394746,"percentOfClass":10.8,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/cldx"}],"updatedAt":"2026-11-05T17:32:05.905Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/cldx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}